This result suggests that these non-toxic and inexpensive compounds have the potential to augment the therapeutic effect of HDAC inhibitors for cancer treatment, and support further research towards exploring the potential for the combination of HDAC inhibitors and acetylated amino acids in various cancers. The gene discussed is HDAC9; the disease is cancer.